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1. INTRODUCTION 
Production of recombinant proteins in highly purified and well characterized form has 
become a major task for the protein chemist within the pharmaceutical and other industries. The 
gram-negative bacterium E. coli is the most commonly used organism for heterologous protein 
production. Some of the reasons are that this organism is very well known and established in 
each laboratory, it grows rapidly and at high density on inexpensive substrates, and there is 
great availability of an increasingly large number of cloning vectors and mutant host strains.  
Recombinant protein production requires the use of a bacterial plasmid construct as vector 
carrying a gene to be expressed and plasmid instability is a significant concern in the academic 
and industrial utilization of microorganisms for protein or DNA production. The most 
commonly used selectable markers to avoid the domination of plasmid-free cells, are antibiotic 
resistance genes. However, antibiotics are expensive compounds and they can contaminate the 
biomass or production product. Given that these contaminations are unacceptable from 
industrial and medical or regulatory perspectives it is necessary to make the assessment of the 
residual antibiotics levels and their subsequent removal which are costly procedures. 
Additionally, the use of antibiotics in intensive culture conditions (high biomass and/or 
continuous culture) is not efficient due to dilution or antibiotic inactivation. Several alternative 
strategies have been developed to reduce the risk that plasmid-free cells overtake a culture and 
one of those is using auxotrophic markers based on complementation of mutation on plasmid 
and deletion in the host chromosome.  
In this thesis an alternative approach to the use of antibiotic selection markers will be 
explored, using an auxotrophic E. coli strain, that has deleted gene for triphosphate isomerase 
(tpiA). TpiA is a central enzyme of glycolysis and its knockout will have tremendous effect on 
growth of the cells. Knock-out strain will not grow on glycerol whereas growth on glucose is 
still possible but with lower rate then usual. It will be transformed with plasmid that 
complements the mutation, has an antibiotic resistance marker and has the gene for sfGFP. It's 
growth and plasmid stability will be observed in different volumes, from shake flasks to 
bioreactor, in batch and fed-batch mode, and compared to parent, non-mutated strain, cultivated 
in pure medium and medium with addition of antibiotic. Plasmid stability will be observed as 
fluorescence while plasmid carries the gene for sfGFP. In addition, new tpiA knock-out strain 
will be created, with lower probability of homologous recombination and creating revertants.  
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2. THEORETICAL BACKGROUND 
2.1. Escherichia coli 
Escherichia coli is a major bacteria of the normal intestinal flora and has huge 
biotechnological importance being the host for a mass-production of recombinant proteins, 
important for industrial as well as for pharmaceutical use. It doesn’t differentiate, sporulate, fix 
nitrogen, photosynthesize, excrete large amounts of protein or grow in exotic environments but 
it is still preeminent in research laboratories for more than a century (Neidhardt, 1987). E. coli 
was discovered in the human colon in 1885 by German bacteriologist Theodor Escherich who 
called it Bacterium coli. The name was later changed to Escherichia coli to honor its discoverer 
(Hacker and Blum-Oehler, 2007).  
Since the early days, scientist chose organisms that were easily accessible, not highly 
virulent and grew well on defined media and E. coli has risen up as the undeniable winner. 
Today we know about E. coli more than about any other cellular form of life (Neidhardt, 1987). 
Its genome was first sequenced in 1997 and large number of its enzymes and regulatory proteins 
have been characterized at the level of reaction mechanism, transcriptional and substrate-level 
regulations. Even some databases have been developed, for instance, EcoCyc, which allows 
easy searches for the sequence, function and regulation of nearly all E. coli genes and proteins 
(Theisen and Liao, 2017). 
 It is a facultative anaerobic and Gram-negative bacillus that measures around 1-3 x 0,4 
– 0,7 µm in size (Figure 1). It grows very quickly and adapts well to metabolic stress. The 
generation time of an E. coli culture is usually between 15 to 30 minutes, while most other 
bacteria that can be cultured have generation times between 20 minutes to an hour (Moulton, 
2014; Stanbury et al., 1995). It grows at a temperature range of 10 – 40 °C and a pH of 7.2. 
Phylogenetically, it is a member of the Enterobacteriaceae, and is closely related to such 
pathogens as Salmonella, Klebsiella, Serratia, and the infamous Yersinia pestis, which causes 
plague (Blount, 2015). 
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Figure 1. Scanning Electron Micrograph of E. coli. (Blount, 2015) 
 Even though it has many advantages as a microbial platform for industrial application 
E. coli has some shortcomings as well. It is sensitive to bacteriophage infection and since it is 
a Gram negative bacterium, its outer membrane contains lipopolysaccharide, also known as 
endotoxin, which evokes strong immune responses in animals. Furthermore E. coli production 
of compounds intended for human or animal consumption requires special clearance to be 
classified as “Generally Recognized as Safe” (GRAS). In addition, E. coli is able to produce 
many compounds but without optimization it is not the best at producing any given compound. 
However this situation is changing as the advanced genetic manipulation tools for E. coli have 
enabled rapid progress in optimizing E. coli in production of many products (Theisen and Liao, 
2017).  
2.1.1. Carbohydrate metabolism in E. coli 
There are three central and constitutive routes of intermediary carbohydrate metabolism 
in enteric bacteria: glycolysis, pentose phosphate pathway and Entner-Doudoroff pathway 
(Neidhardt, 1987).  
Glycolysis is the first step in the breakdown of glucose to extract energy for cellular 
metabolism and nearly all living organisms carry out glycolysis as part of their metabolism 
(Figure 2). Process is anaerobic and takes place in the cytoplasm of cells. It consists of two 
parts. In the first part energy is being consumed to modify and split glucose in two three-carbon 
molecules which are then being metabolized to pyruvate through energy releasing steps in the 
second part.  
4 
 
 
Figure 2. Glycolysis (Lodish et al., 2008) 
In the last years, as a consequence of biodiesel business, glycerol has evolved as an 
interesting carbon source for fermentation processes. Producing biodiesel from animal fats and 
vegetable oils generates about 10% (w/w) glycerol as the main by-product and this may cause 
an issue as it cannot be disposed of in the environment. One of the possible solutions is to use 
glycerol as a carbon and energy source for microbial growth in industrial microbiology (da 
Silva et al., 2009).  
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Escherichia coli can utilize glycerol as the sole carbon and energy source. It is imported 
through the cytoplasmic membrane by a facilitator protein and it can be metabolized on two 
alternative pathways, depending on the growth conditions, that both end with dihydroxyacetone 
phosphate (DHAP). The first and also the preferred one consists of a phosphorylation step by a 
glycerol kinase to yield L-glycerol-3-phosphate followed by an oxidation step due to the 
appropriate dehydrogenase leading to DHAP. The alternative pathway consists of an oxidation 
step by glycerol dehydrogenase to yield dihydroxyacetone followed by phosphorylation by 
DHA kinase to give DHAP. In the end DHAP must be fed into the general glycolytic pathway 
through isomerisation by triosephosphate isomerase (tpiA) as glyceraldehyde-3-phosphate 
(Velur Selvamani et al., 2014). 
Triosephosphate isomerase (tpiA) is a dimeric enzyme composed of identical subunits 
and one of the central enzymes of glycolysis (Pychersky et al., 1984). Without this enzyme cells 
are unable to grow on glycerol or succinate alone, but grow on succinate and other appropriately 
supplemented with ribose or glycerol. TpiA mutant strains are very sensitive to accumulation 
of dihydroxyacetone phosphate whose toxicity is related to enzymatic conversion to the 
bactericidal agent methylglyoxal. Although there is a glyoxylase that converts methyglyoxal to 
D-lactate, and thus a pathway for dihydroxyacetone phosphate dissimilation, it is of low 
capacity and insufficient to prevent methylglyoxal toxicity in the tpiA mutant (Neidhardt, 
1987).  
2.1.2. Growth kinetics of E. coli 
 Growth of an E. coli culture can be measured in multiple ways. Most methods rely on 
an estimate of cell mass by optical absorbance at a particular wavelength or on measuring the 
cells dry mass after centrifugation of the culture and subsequent drying of the cell pellet. The 
lack of these methods is the fact that you are measuring both living and dead cells. This shortage 
can be exceeded by plating the culture on agarose or LB plates over the lifetime but that requires 
a lot of work.  
 Typically there are four phases to the growth of a bacterial culture like E. coli (Figure 
3). First phase is the lag phase, during which it appears that cells are not growing. It is the time 
of adaptation of the cells to the new environment and preparation for propagation. Cells are 
synthesizing needed enzymes and intermediates and consequently increasing their volume. 
Length of this phase depends on current level of enzymes and intermediates in the cells that are 
being inoculated and its relation towards level needed for the beginning of reproduction. In 
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commercial process the length of the lag phase should be reduced as much as possible and this 
may be achieved by using the right inoculum. If the cells in the inoculum are young and the 
new environment is favorable this phase will be really short or even completely absent.  
Following comes the period during which cells grow at a constant, maximum rate and 
this period is known as exponential or log phase. During the exponential phase nutrients are in 
excess and the culture is growing at its maximum specific growth rate. This phase is being 
exploited in processes for production of microbial biomass and primary metabolites and it is 
desirable to last as long as possible.  
Growth results in the consumption of nutrients, which may lead to exhaustion of some 
essential nutrient in the medium (substrate limitation), and the excretion of microbial products, 
which may generate accumulation of some toxic product. Both of the cases or their combination 
cause the decrease of the growth rate of the culture which results in stationary phase of growth 
where the growth rate has declined to zero. It is difficult to tell if the cells culture is still dividing 
and dying at the same rate or the culture as a whole has stopped growing and dividing. The 
stationary phase is misnomer in terms of the physiology of the organism as the population is 
still metabolically active during this phase and may produce secondary metabolites which are 
not produced during exponential phase. Additionally cells change their composition. Nucleic 
acid share is decreasing as well as the spare ingredients are accumulating.   
As the growth of the culture continues late into the stationary phase, the culture will 
eventually reach a phase of decline, also known as death phase, where carbon sources are 
exhausted and/or autotoxins are inhibiting transcription and/or translation. Abrupt speed 
depends on microorganism and environmental conditions (Marić and Šantek, 2009; Moulton, 
2014; Stanbury et al., 1995). 
 
Figure 3. Growth curve of a typical microbial culture (Anonymous, 2009) 
7 
 
2.1.3. Recombinant protein production in E. coli  
Proteins have multiple functions, they are catalyzers of metabolic reactions, structural 
components of biological assemblies, they take part in inter and intracellular interactions and 
cell signaling events that are critical for life. Their production plays an important role for 
today’s medicine especially after the development of recombinant DNA technologies (rDNA) 
in the late 70’s. In early 80's FDA approved clinical use of recombinant human insulin from 
recombinant E. coli for treatment of diabetes, being the first recombinant pharmaceutical to 
enter the market. Since then, other recombinant DNA drugs have been marketed in parallel with 
the development and improvement of several heterologous protein production systems. This 
has generated specific strains of many microbial species adapted to protein production, and has 
allowed the progressive incorporation of yeasts and eukaryotic systems for this purpose (Ferrer-
Miralles et al., 2009). Bacterial expression systems for heterologous protein production are 
attractive because of their ability to grow rapidly and at high density on inexpensive substrates, 
their often well-characterized genetics and the availability of an increasingly large number of 
cloning vectors and mutant host strains (Terpe 2006). Among the 151 protein-based 
recombinant pharmaceuticals licensed up to January 2009 by the FDA and EMEA, 45 (29.8%) 
are obtained in Escherichia coli.  
E. coli is the first-choice microorganism for the production of recombinant proteins, and 
widely used for cloning, genetic modification and small-scale production for research purposes. 
This is not a big surprise as the historical development of microbial physiology and molecular 
genetics was mainly based on this species. It resulted in a steady accumulation and worldwide 
use of both information and molecular tools, such as engineered phages, plasmids and gene 
expression cassettes. However, there are several obstacles to the production of quality proteins 
that limit its application as a factory for recombinant pharmaceuticals. Recombinant proteins 
obtained in E. coli lack the post-translational modifications which are present in most of 
eukaryotic proteins (Ferrer-Miralles et al., 2009). Another disadvantage for therapeutic use of 
produced recombinant proteins in E. coli is the accumulation of lipopolysaccharide, endotoxins, 
which are pyrogenic in humans and other mammals. Proteins for this application must be 
purified in a second step to become endotoxin-free (Petsch and Anspach, 2000). 
Approved therapeutic protein-based products from E. coli include hormones (human 
insulin and insulin analogues, calcitonin, parathyroid hormone, human growth hormone, 
glucagons, somatropin and insulin growth factor 1), interferons (alfa-1, alfa 2a, alfa-2b and 
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gamma-1b), interleukins 11 and 2, light and heavy chains raised against vascular endothelial 
growth factor-A, tumor necrosis factor alpha, cholera B subunit protein, B-type natriuretic 
peptide, granulocyte colony stimulating factor and plasminogen activator. Most of the 
recombinant pharmaceuticals produced in E. coli are focused on the treatment of infectious 
diseases or endocrine, nutritional and metabolic disorder disease groups (Ferrer-Miralles et al., 
2009).  
2.1.4. Bioreactor cultivation of E. coli 
Fermentations may be carried out as batch, continuous and fed-batch processes and the 
mode of operation is usually dictated by the type of product being produced.  
Batch culture, as a plain example of nonstationary microbial process, is a closed culture 
system which contains an initial, limited amount of nutrient. Fermenter is first filled with the 
raw material, then sterilized and inoculated. Process is being carried on under optimum pH, 
temperature and aeration until the substrates are exhausted and the product is formed. Microbes 
in the fermenter go through lag, log, stationary and decline phases and the product remains in 
the fermenter until the finalization of fermentation. After the fermentation, the product is 
extracted and the fermenter is cleaned and sterilized before the next round. It has huge 
application in the industrial production, especially for the production of secondary metabolites 
whose production is not associated with the growth of the microbes. It is easy to set-up and the 
run, the risk of contamination is low, control methods are easy and quick, there is less work 
needed and it requires less initial investment. But on the other side you have less control over 
the growth of the microbes and the production of desired products, environmental conditions in 
the fermenter are not constant and the turnover rate is lower. 
Exponential growth in batch culture may be prolonged by the addition of fresh medium 
to the vessel. If the medium has been designed in a way that growth is substrate limited by some 
component in the medium and non-toxin limited, exponential growth will proceed until the 
additional substrate is exhausted. Usually an overflow device is fitted to the fermenter in a way 
that the added medium displace an equal volume of culture from the vessel and then continuous 
production of cells could be achieved. If medium is fed continuously to such culture at a suitable 
rate, a steady state is achieved eventually, that is, formation of new biomass by the culture is 
balanced by the loss of the cells from the vessel. Unlike batch fermentation, in continuous 
fermentation process continues to run for a long period of time with the addition of nutrients 
and harvesting the metabolites at regular intervals. It is an open system and thus risk of 
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contamination is higher but it gives you more control on the growth and production and 
environmental conditions in the fermenter are kept constant. Turnover rate is higher and 
exponential growth rate of microbes is maintained. It is suitable for the production of primary 
metabolites like organic or amino acids. It is not easy to set-up, run and control and demands 
larger initial investment and labor demand. 
The term fed-batch culture was introduced in 1973. to describe batch culture which are 
fed continuously or sequentially with medium, without removing of culture fluid. A fed-batch 
culture is established initially in batch mode and is then fed with fresh medium which results 
in an increase of volume. The use of fed-batch culture by the fermentation industry takes 
advantage of the fact that the concentration of the limiting substrate may be maintained at a 
very low level, thus avoiding the repressive effects of high substrate concentration, catabolite 
repression and glucose effect but also to reach high densities of biomass within short cultivation 
time. Whenever the specific growth rate and/or product formation are not monotonic functions 
of the concentration of the substrate, a fed-batch fermentation may be preferable. It allows 
extending the duration of the process and increases productivity, product yield and substrate 
utilization compared to batch fermentation. 
Fundamental part of fed-batch fermentation is determining the optimal feed rate of 
substrate. Specific oxygen-uptake rate is directly proportional to specific growth rate and the 
most common way of controlling the nutrient addition is to link to a feed-back control loop 
using a dissolved oxygen electrode as the sensing element. If the dissolved oxygen 
concentration declines below the set point, meaning the cells are growing exponentially and the 
demand for oxygen is high, then the feed rate is reduced and when the dissolved oxygen 
concentration rises above the set point, meaning substrate is limiting the growth, feed rate is 
increased. A pH electrode may also be used as a sensing unit in fed-batch control loop for the 
control of oxygen demand – oxygen limitation being detected by the development of acidic 
conditions. Other ways include controlling the feeding by determination of the specific growth 
rate or by measuring limiting substrate concentration (Cutayar and Pollon, 1989; Kleist, 2002; 
Marić and Šantek, 2009; Modak et al., 1986; Stanbury et al., 1995). 
2.2. Plasmid stability 
Expression systems based on E. coli mostly depend on the presence of at least one 
plasmid which has to be segregated into dividing cell during growth. The successful subdivision 
of plasmids on the daughter cells is a central problem in plasmid dependent expression systems 
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and because of that a variety of methods has been developed in order to achieve plasmid 
stability. 
The most commonly used method is adding antibiotics into the cultivation medium and 
placing genes for antibiotic resistance on the plasmid carrying the target gene. All cells without 
plasmid in the antibiotic containing medium will be killed or least prevented from growth. This 
strategy is widely used in research but in industrial biotechnology, the addition of antibiotics 
can be generally excluded. Antibiotics are too expensive to be used in industrial scale 
production and elimination of antibiotics from media and waste stream may be required during 
downstream processing. Plasmids without antibiotic resistance genes are especially preferred 
for gene therapy or gene vaccination. The main reason is that if the resistance genes are 
expressed in the human body it may lead to unwanted side effects. Another reason is that 
resistance genes may be transformed via horizontal gene transfer onto pathogenic 
microorganisms and making them resistant to the particular antibiotic. This is a growing 
problem today, especially in hospitals, and will be discussed later in this thesis. Another 
growing problem are allergic reactions, which could be observed in animals when plasmid DNA 
is used for vaccination. Furthermore, resistance is sometimes based on producing destructive 
enzymes to neutralize antibiotics. For instance, resistance to β-lactam antimicrobial agents, like 
Ampicillin, in E. coli is primarily mediated by β-lactamases, which hydrolyze the β-lactam ring 
and thus inactivate the antibiotic (Brinas et al., 2002). Gene for β-lactamases is often placed on 
plasmids, to make the plasmid-containing bacteria Ampicillin resistant. But that brings up a 
new problem. β-lactamases are mostly secreted into the medium and degrade the Ampicillin 
added to it so stability pressure gets lost quite fast. Therefore, other methods for plasmid 
stabilization are in high demand.  
Another simple strategy in trying to keep a high segregational plasmid stability is using 
plasmids of high copy number and expecting that the statistical distribution of plasmids during 
cell division may always yield cells with at least some plasmids. This works fine as long as the 
average plasmid copy number is homogeneous, but as soon as cells with very low plasmid copy 
numbers show up during high growth rates, cells might have not enough time to synthesize 
plasmids in high copy numbers. As they are additional metabolic burden, plasmids may be lost 
completely, since plasmid-free cells would gain a growth advantage in comparison to plasmid-
bearing cells. If plasmid free cells arise early at the beginning of cultivation, they can overgrow 
the whole population. At the end, there might be a lot of biomass but no plasmid and 
subsequently no recombinant product.  
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In some cases, changes in the cultivation strategies, mainly by decreasing the specific 
growth rate, may lead to sufficient plasmid stability. This can be achieved by reducing the 
cultivation temperature or changing the carbon source of the medium. However, most methods 
are based on adding some stabilizing elements by genetic engineering. 
 Nature also has some strategies to guarantee plasmid segregation. For instance, single 
copy plasmids often show sophisticated stabilizing mechanisms like that based on the par-
system which leads to a controlled distribution of plasmids, similar to the highly organized and 
controlled chromosome distribution in higher organisms. The par-system consists of at least 
two protein-coding genes and one special site on the plasmid for controlled distribution in the 
dividing cell. Other systems lead to the post-segregational killing of plasmid-free cells and need 
the genetic information of a toxin and its corresponding antidote, with the antidote on the target 
plasmid. Such a combination was recently applied for the development of a Streptomyces based 
protein expression system. 
There are some special systems developed for industrial production of recombinant 
proteins in which production strains were mutated so that they were not able to produce an 
essential substance or protein. One of their essential genes was knocked out on the chromosome 
and was placed on a plasmid. Strain with the plasmid was then cultivated in the medium which 
does not contain the missing substance and therefore only those cells, who carry the plasmid, 
could survive and divide.  
One of the first methods that work in previously described way that was developed for 
commercial use was the valS-system. The wild-type gene for valyl-tRNA synthetase (valS) of 
the host carries a temperature-sensitive mutation and the gene without mutation is placed on a 
plasmid. For transformation the host is grown at 30°C and cultivations of transformed strain are 
performed at 37°C. During cultivations mutated synthetase on the chromosome loses its 
function and only cells carrying the valS-harboring plasmid can survive and grow. 
Nevertheless, valS gene is still around on the chromosome and the selection pressure favors a 
recombination of the mutated valS on the chromosome and the wild type valS on the plasmid. 
Such a recombination produces revertants with no selection pressure by valS and leads to 
plasmid instability. One way to reduce the probability of this recombination is the complete 
knockout of the chromosomal gene but in that case of valS this would not allow to obtain viable 
cells for transformation and, for that reason, would not be practicable. 
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Another strategy is the Operator-Repressor-Titration (ORT) based on negative 
regulation of an essential chromosomal gene by an operator sequence allowing the binding of 
a constitutively expressed repressor protein. In order to allow expression of the essential gene 
and survive, the cell has to titrate the repressor molecules against a similar operator sequence 
that may be present in multiple copies on the target plasmid to be maintained. An example for 
this is amber nonsense mutation introduced into the essential thyA gene in the chromosome 
causing thymidine auxotrophy, that was overcome by recombinant plasmids carrying a 
suppressor tRNA, which allowed antibiotic-free plasmid selection and also recombinant 
luciferase reporter expression in eukaryotic tissues and in tumor cells.  
Additional strategy is to make auxotrophic mutants in a way that auxotrophy can be 
overcome by supplements in the medium so that competent cells can be prepared and 
transformed using such a supplemented medium. This may be achieved by knockout of an 
essential gene for example for the synthesis of an amino acid like glycine or for some of the 
enzymes in essential metabolic pathways like tpiA. In E. coli JW3890-2, strain from Keio 
knock-out collection, the tpiA gene is knocked out of E. coli leading to an auxotrophic strain 
which can be cultivated in full medium, like LB, but would not grow in a medium based on 
glycerin, like HSG. The tpiA gene can then be cloned on an expression vector under the control 
of a constitutive promoter and transformed to the strain. This would allow transformants to 
grow in HSG medium and keep the plasmid through generations. The problem with this strain 
is that tpiA knockout was performed in a way that the promoter and terminator of tpiA gene are 
still present on the strains genome. This may lead to homologous recombination of the tpiA 
gene back to the genome and otherwise stated make possibility of revertants showing up. To 
avoid this obstacle, another E. coli tpiA knockout strain, that doesn’t contain any part of the 
tpiA gene, was created in later described experiments (Baba et al., 2006; Friehs, 2004; Velur 
Selvamani et al., 2014).  
2.3. Antibiotic resistance 
Antibiotics are specific metabolic products that have high physiological activity towards 
the specific groups of organisms such as viruses, bacteria, fungi, protozoa and malignant 
tumors, while inhibiting their growth or destroying them (Šušković and Kos, 2017). The modern 
era of antibiotics started when Sir Alexander Fleming discovered penicillin in 1928 (Ventola, 
2015).  Introduction of penicillin brought us to discovery of many classes of antibiotics which 
put some of the most infectious diseases under control (Penesyan et al., 2015).  
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Antibiotics have revolutionized medicine and saved countless lives. Their discovery was a 
turning point in human history. Unfortunately, use of these drugs has been accompanied by the 
rapid appearance of resistant strains (Davies and Davies, 2010). Antibiotic resistance is a direct 
result of the use of antibiotics. The greater is the volume of used antibiotics, the greater are the 
chances that antibiotic resistant populations of bacteria will overcome the others in the contest 
for survival of the fittest at the bacterial level (Gelband et al., 2015). 
Understanding the mechanisms of resistance has become a serious issue over the past 
decades and today there is a large pool of information about how bacteria can develop drug 
resistance. Biochemical and genetic aspects of antibiotic resistance mechanisms in bacteria are 
shown in Figure 4. (Džidić et al., 2008). Bacteria resist the effects of antibiotics by  
 producing destructive enzymes to neutralize antibiotics, 
 modifying antimicrobial targets so that drugs cannot recognize them,  
 pumping antibiotics out, 
 preventing antibiotics from entering by creating a biofilm of reducing 
permeability,  
 creating bypasses that allow bacteria to function without the enzymes targeted by 
antibiotics and thousand other variations (Penesyan et al., 2015).  
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Figure. 4. Biochemical and genetic aspects of antibiotic resistance mechanisms in bacteria 
(Džidić et al., 2008) 
Mechanisms to overcome bacterial resistance stretch from basic hygienic practices to stop 
the spread of bacteria in hospital to the synthesis of agents with improved antimicrobial activity 
(Neu 1992). Antibiotic use can be rationalized by reducing the need for antibiotics through 
better public health, by suppressing unnecessary use, and by improving access where use is 
needed (Gelband et al., 2015).  
Antibiotic control programs are proven effective ways to reduce inappropriate use of 
antibiotics in hospitals. The responsibility of reducing resistance lies with doctor who prescribes 
antibiotics and with patients who demand them when the illness is viral and when antibiotics 
are not indicated. It is also important that the pharmaceutical industry promotes only appropriate 
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use of antibiotics for humans and for animals. In addition, avoiding the use of antibiotics in 
industrial scale production of proteins should be priority (Neu, 1992).  
2.4. Green fluorescent protein 
The diverse biochemical and photo physical properties of fluorescent proteins have 
enabled the generation of a growing palette of colors, providing unique opportunities for their 
use in a variety of modern biology applications (Stepanenko et al., 2011). Since its discovery 
in 1962 and subsequent cloning of the Green fluorescent protein (GFP) in 1994 the jellyfish 
Aequorea fluorescent proteins are the most widely used reporter proteins in all areas of biology. 
Due to their unique independence from cellular chaperones and non proteinogenic compounds, 
other than molecular oxygen, for chromophore maturation they outcompete other genetically 
encoded fluorescent proteins and other dyes for many in vivo applications (Dammeyer and 
Tinnefeld, 2012). The crucial breakthroughs came with the cloning of the gene and the 
demonstrations that expression of the gene in other organisms creates fluorescence. The gene 
contains all the information necessary for the posttranslational synthesis of the chromophore, 
and no jellyfish-specific enzymes are needed. That’s why GFP has become well established as 
a marker of gene expression and protein targeting in intact cells and organisms (Tsien, 1998).  
The structure of correctly folded GFP consists of an internal fluorophore surrounded by 
a tight beta-barrel (Dammeyer and Tinnefeld, 2012). Wild-type GFP is temperature sensitive 
and misfolds when expressed in E. coli. For this reason new, robustly folded version of GFP, 
called superfolder GFP (Figure 5), that folds well even when fused to poorly folded 
polypeptides, was generated. Compared to ‘folding reporter’ GFP, a folding-enhanced GFP 
containing the ‘cycle-3’ mutations and the ‘enhanced GFP’ mutations F64L and S65T, 
superfolder GFP shows improved tolerance of circular permutation, greater resistance to 
chemical denaturants and improved folding kinetics. The fluorescence of Escherichia coli cells 
expressing proteins as fusions with superfolder GFP is proportional to total protein expression 
(Pedalacq et al., 2006). 
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Figure 5. Structure of sfGFP (Tookmanian et al., 2015) 
sfGFP absorbs light with an excitation maximum of 485 nm and fluoresces with an 
emission maximum of 510 nm.  
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Chemicals 
 1 kb DNA Ladder, Plasmid Factory GmbH & Co. KG, Bielefeld, Germany 
 Agar-agar, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Agarose NEEO Ultra-Qualität, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Ampicillin Natriumsalz, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Calcium chloride, Applichem GmbH, Darmstadt, Germany 
 Di-potassium hydrogen phosphate, VWR Corporation, Radnor, PA, USA 
 GeneRuler DNA Ladder Mix, Thermo Scientific,Waltham, MA, USA 
 Glycerin (99 %), Emery Oleochemicals GmbH, Düsseldorf, Germany 
 Kanamycin sulphate, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 L-arabinose, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Magnesium sulphate hydrate, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Natrium carbonate, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Natrium chloride, Fisher Scientific GmbH, Schwerte, Germany 
 Natrium hydroxide, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Phosphoric acid, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Pluronic (antifoam), BASF  SE, Ludwigshafen, Germany 
 Potassium di-hydrogen phosphate, Applichem GmbH, Darmstadt, Germany 
 Roti®-GelStain, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Soya peptone, UD Chemie GmbH, Wörrstadt, Germany 
 Tris, Fisher Scientific GmbH, Schwerte, Germany 
 Tris-HCl, Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 Yeast extract, Ohly GmbH, Hamburg, Germany  
3.1.2. Buffers and solutions 
 Ampicillin solution (100 mg/mL) 
Ampicillin   100 mg  
Distilled water   up to 1 mL 
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 Kanamycin solution (50 mg/mL) 
Kanamycin   50 mg  
Distilled water   up to 1 mL 
 Buffer 1 (pH = 7,4) 
CaCl2    0,1 M 
Tris-HCl   2 mM 
Distilled water   up to 100 mL 
 Buffer 2 (pH = 7,4) 
CaCl2    0,1 M 
Tris-HCl   2 mM 
Glycerin   10 % 
Distilled water   up to 100 mL 
 TAE BUFFER (pH = 8) 
Tris     40 mM 
Acetic acid   20 mM 
EDTA    1 mM 
Distilled water  up to 1 L 
3.1.3. Culture medium 
 LB (Lysogeny broth) media (pH = 7,4) 
Soya peptone   10 g 
Yeast extract   5 g 
NaCl    10 g 
Distilled water   up to 1 L 
For making plates 15 g of agar-agar was added before autoclaving 
 HSG media (pH = 7,4) 
Soya peptone   13,5 g 
Yeast extract   7 g 
Glycerin (99 %)  14,9 g 
NaCl    2,5 g 
K2HPO4   2,3 g 
KH2PO4   1,5 g 
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MgSO4 x H2O   0,14 g 
Distilled water   up to 1 L 
 Feeding medium 
Glycerin (99%)  527 g 
Yeast extract   90 g 
MgSO4 x H2O   2 g 
Distilled water   up to 1 L 
3.1.4. Enzymes 
 Phusion R High-Fidelity DNA Polymerase, New England Biolabs, Ipswich, MA, USA 
 Dream Taq, Thermo Scientific,Waltham, MA, USA 
3.1.5. Primers 
 Primers used for PCR during experiments were custom made by INVITROGEN, 
Carlsbad, Kalifornija, SAD 
3.1.6. Bacterial strains 
In experiments described in this thesis strain Escherichia coli BW25113 and its 
derivatives were used. It is a common laboratory strain that was created in the laboratory of B.  
L. Wanner as a derivative of the F-, λ-, E. coli K-12 strain BD792. Today it is known as the 
parent strain for the Keio collection, a major resource consisting of approximately 4,000 single-
gene deletion mutants. Keio collection was utilized in a method taking advantage of the 
bacteriophage lambda red recombination system to perform gene disruptions with double-
stranded PCR products. The strain and its derivatives are being used in countless laboratories 
for a variety of studies, including systematic phenotypic surveys and synthetic biology efforts. 
Apart from the Keio parent strain, its derivative with a tpiA knock-out, Escherichia coli 
JW3890-2, was also used, to show how plasmid stability can be enhanced without using 
antibiotics. Later in text it is referred as Keio tpi-A knock-out. In addition, new Keio tpiA 
knockout strain, was created to avoid possibility of homologous recombination which can 
happen between E. coli JW3890-2 and plasmid carrying tpiA gene, as described later on. Later 
in text it is referred as Keio new tpiA knock-out.  
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Table 1. List of used bacterial strains with their genotype and source 
STRAIN GENOTYPE SOURCE 
Escherichia coli BW25113 
Δ(araD-araB)567, 
ΔlacZ4787(::rrnB-3), lambda−, 
rph-1, 
Δ(rhaD-rhaB)568, hsdR514 
CGSC, Yale University 
Escherichia coli JW3890-2 
Δ(araD-araB)567, 
ΔlacZ4787(::rrnB-3), lambda−, 
rph-1, 
Δ(rhaD-rhaB)568, ΔtpiA778:kan 
hsdR514 
CGSC, Yale University 
Escherichia coli BW25113  
new tpiA knock out 
Δ(araD-araB)567, 
ΔlacZ4787(::rrnB-3), lambda−, 
rph-1, 
Δ(rhaD-rhaB)568, ΔtpiAnew:kan 
hsdR514 
Made in Laboratory of 
Fermentation Technologies 
3.1.7. Plasmid 
All of the strains used in these experiment were transformed with pBR322-P100sfGFP-
tpiAO constructed in the Laboratory for Fermentation technologies (Figure 6). Genes located 
on this plasmid are listed with description in Table 2. Plasmid contains strong constitutive 
promoter P100 so the expression of sfGFP does not have to be induced. 
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Figure 6. Map of pBR322-P100sfGFP-tpiAO made with SnapGene software, GSL 
Biotech LLC 
Table 2. Explanation of abbreviations on plasmid map showed on Figure 6. 
ABBREVATION DESCRIPTION 
pBR322 origin of replication, derived from the plasmid ColE1 
sfGFP super folder green fluorescent protein 
tpiA Tri phosphate isomerase 
Rop 
Repressor of primer, keeps the plasmid number at 15 to 20 
copies per cell 
TcR Tetracycline resistance 
AmpR Ampicillin resistance 
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3.1.8. Equipment 
 Agarose gel electrophoresis system MINI GEL II, VWR International GmbH, 
Darmstadt, Germany 
 Analytical balance PM34-K DeltaRange, Mettler – Toledo GmbH, Gießen, Germany 
 Autoclave D-65, Systec GmbH, Linden, Germany 
 Autosampler Fraction collector FC 2038, Gilson International B.V. Deutschland, 
Limburg-Offheim, Germany 
 Centrifuges 3-30 KS and 1-15, Sigma Laborzentrifugen GmbH, Osterode am Harz, 
Germany  
 Electrophoresis power supplier Standard Power Pack P25, Biometra GmbH, 
Göttingen, Germany 
 Freezer MDF – U5386S, SANYO Electric CO., Ltd, Osaka, Japan 
 Electroporator GENE PULSER II, Bio-Rad Laboratories, Hercules, Kalifornija, SAD 
 Laboratory equipment (pipets, pipette extensions, petri dish, flasks, measurement jugs, 
beakers) 
 Magnet mixer, IKAMAG REO, IKA, Staufen, Germany 
 Nanodrop Spectrophotometer ND-1000, Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
 pH- meter 691, Metrohm AG, Herisau, Switzerland  
 Precision balance AE 260 DeltaRange, Mettler – Toledo GmbH, Gießen, Germany 
 Shaker Lab-Shaker LS – X, Kuhner AG, Birsfelden, Switzerland 
 Spectrofluorometer RF-530PC, Shimadzu GmbH, Duisburg, Germany 
 Spectrophotometer BioPhotometer, Eppendorf AG, Hamburg, Germany 
 Transiluminator BioDocAnalyze, Biometra GmbH, Göttingen, Germany  
 Ultrasound homogenizer, Sonifier 450, BRANSON Ultrasonics, Danbury, USA 
 Vortex – Genie 2, Scientific Industries, Inc., Bohemia, New York, SAD 
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3.2. Methods  
3.2.1 Cultivation 
Cells were cultivated at 37 °C and pH 7,2 in different volumes, from shake flasks to 
fermenter. For each strain and each volume cultivation was performed two times. 
3.2.1.1. Preculture setting 
 To grow preculture, 100 μL of glycerine culture was added to 30 mL of HSG medium 
and grown in 300 mL flasks without baffles. If needed 100 µL of ampicillin solution was added 
to the medium. Preculture was cultivated on shaker (120 rpm, 50 mm rotation radius) overnight 
on 37º C. 
3.2.1.2. Shake flasks cultivation 
 100 mL of medium was added to 500 mL flask with four baffles. If needed, 100 µL of 
ampicillin solution, was added to the medium. Medium was inoculated with overnight cell 
culture to reach the start OD600 = 0,2 and flask was placed on a shaker (120 rpm, 50 mm rotation 
radius) at 37 °C (Figure 2). Samples for measuring OD600 and fluorescence and were manually 
taken every hour.  
 
Figure 7. Shake flask cultivation  
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3.2.1.3. Batch cultivation   
Bioreactor NLF 3 (Figure 8) was filled up with 5 L of medium and sterilized. Process 
parameters during fermentation (pH, temperature, overpressure, air flow, pO2, stirrer speed) 
were automatically controlled and measured during the fermentation using software 
BiOSCADA Lab by BiOENGINEERING. Conditions of cultivation are showed in Table 3.  
Table 3. Parameter of cultivation in bioreactors 
PARAMETER VALUE 
pH 7,2 
Temperature 37 °C 
Overpressure 0,2 bar 
Air flow 5 NL/min 
pO2 60 % 
Stirrer speed 200 – 1500 min-1 
 
pH was regulated with 10 % phosphoric acid and 2 M NaOH, which were sterilized 
prior to use as well as antifoam Pluronic. For control of oxygen concentration stirrer cascade 
was used. 
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Figure 8. Bioreactor connected to control cabinet and acid/base/antifoam pumps  
Bioreactor was inoculated with 50 mL of overnight cell culture. Samples were taken 
with auto sampler every hour or every 2 hours (depending on the growth rate) aseptically using 
a steam-serializable sampling valve of bioreactor. 
Bioreactor specification and system scheme is attached in Appendix. 
3.2.1.4. Fed-batch cultivation 
 The same bioreactor (NLF3) and software (BiOSCADA) were used as for batch 
cultivation. After sterilization automatically controlled pump for feeding medium was 
connected to the bioreactor. Cultivation was started in the same way as in batch fermentation 
and feeding was controlled by pO2. Feeding media was being added when pO2 fell under 60 % 
and it was turned off if pO2 went under 30 %.  
3.2.2. Sample analysis 
 Growth of the cells was measured by OD600 and plasmid stability by fluorescence 
measurement. For optical density measurement samples were simply poured into PS cuvette 
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and measured under 600 nm compared to blank (sterile medium). OD600 was converted to cell 
concentration with formula: 
X [g/L] = OD600 x 0,39      (1) 
Specific growth rate was calculated for exponential phase of growth by using formula: 
𝜇 = ଵ
௧
𝑙𝑛 ௑
௑బ
       (2) 
For fluorescence measurement cells needed to be disintegrated. Cell suspension from 
cultivation was disintegrated by ultrasonic lysis. 1 mL of sample (taken at each time point) was 
put in an ice-water bath and sonicated in three cycles for 30 seconds with 30 seconds break in 
between the cycles. The efficiency of sonication was monitored by microscopy.  
After lysis samples were centrifuged for 5 minutes under 14 000 rpm. In the end 1 mL 
of supernatant was poured into PS cuvette and the fluorescence was measured through an 
excitation filter of 485 nm and emission filter of 510 nm. 
Samples were also plated on LB plates with and without antibiotic to check their 
microbiological purity and appearance.  
3.2.3. Transformation of bacterial strain 
Keio parent and Keio knockout strains were transformed with pBR322-P100sfGFP-
tpiAO previously described in chapter 3.1.7. 
3.2.3.1. Making of competent cells 
Competent cells are ready to use bacterial cells that possess altered cell walls by which 
foreign DNA can be passed through easily. There are some naturally competent bacteria but E. 
coli is not one of them. In this experiment cells were made competent with calcium chloride.  
60 mL of LB-media was poured into 300 mL Erlenmeyer flask and inoculated with 
overnight cell culture to reach OD600 = 0.2. It was then cultivated on the shaker at 37 °C until 
it reached OD600 = 0.8 – 0.9. The culture was then transferred to plastic tubes and left on ice for 
15 minutes. After cooling down culture was centrifuged for 10 minutes on 4 000 g at 4 °C. The 
supernatant was thrown away and cells are resuspended in 2 mL of Buffer 1. Resuspended cells 
were then centrifuged again on 4 000 g at 4 °C. The supernatant was thrown away again and 
cells were resuspended in 2 mL of Buffer 2. Cells were then portioned in Eppendorf tubes. 
Liquid nitrogen was used to shock freeze the cells and they were stored under -80 °C  
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3.2.3.2. Transformation of competent cells 
In this experiment cells were transformed using heat shock treatment. For 
transformation 100 µL of competent cells was melted on ice. 2 µL of DNA was added to cells 
and it was incubated on ice for 20 minutes. After cooling down it was first incubated on 30 
seconds on 42 °C and then it was put on ice for 2 minutes. After heat shock 500 µL of LB media 
was added to suspension and it was incubated for 1 hour at 37 °C on a shaker. In the end cells 
were centrifuged for 2 minutes under 7 000 rpm and room temperature. 500 µL of supernatant 
was thrown away and cells were resuspended in 100 µL and plated on LB-Amp plates.  
3.2.4. Disruption of a chromosomal DNA fragment  
Electro component cells of the Keio parent strain were transformed with pKD46 plasmid 
and plated on LB – Amp plates which were put overnight at 28 °C. pKD46 carries the λ red 
genes behind the araBAD promoter and is temperature sensitive. 
One colony was then picked from the plate and obtained in shake flask with 10 mL of 
LB medium with Ampicillin at 28 °C overnight. Next day 2 lid-punctured microfuge tubes with 
1.4 ml of fresh LB medium with Ampicillin were inoculated with 30 µL of the overnight culture. 
Tubes were then incubated on the shaker at 30 °C for 3 hours. Afterwards 50 µL 10% L-
arabinose was added to each one of the tubes to induce expression of the recombination 
proteins. Tubes were incubated on a shaker at 37 °C for one hour. After incubation culture was 
centrifuged for 30 seconds at 11 000 rpm at 2 °C and washed with chilled water 2 times. In the 
end cells were resuspended in 30 µL of water.  
2 µL of prepared linear pKD13 fragment with homology arms was added to each of the 
two micro centrifuge tubes. The mixture was then pipetted into the chilled electroporation 
cuvettes. It was electroporated at 1350 V, 10 µF and 600 Ohms. After electroporation 1 mL of 
LB medium without antibiotics was added to the cuvette. Cells were resuspended carefully by 
pipetting up and down and incubated with shaking for 3 hour at 37 °C.  
 After incubation culture was centrifuged for 2 minutes at 7 000 rpm. Supernatant was 
thrown away and the rest (around 100 µL) was plated on LB – Kan plates (15 µg/mL) at 37 °C 
overnight.  
 
 
28 
 
3.2.5. PCR amplification 
 Checkout of the disruption was performed using PCR amplification and gel 
electrophoresis of amplified fragment. Colonies grown on plates were picked up and suspended 
in 50 µL of sterile distilled water which is then used as a PCR template. Suspension for PCR 
was prepared as showed in Table 4. 
Table 4. Suspension for PCR 
Component Volume [µL] 
H2O 83,5 
dNTP 2 
Primer 1 2 
Primer 2 2 
Buffer (10x) 10 
Dream Taq polymerase 1 
 
Total volume of 100 µL of suspension was proportioned in 5 PCR Eppendorf tubes. In 
each tube 1 µL of template was added. PCR was programmed as shown in Table 5. 
Table 5. PCR procedure  
Temperature 
[°C] 
Time [min] 
95 5 
95 0,5 
Loop 35x 52 0,5 
72 1 
72 5 
 
 After amplification fragment was loaded on 1% agarose gel. Gel electrophoresis was 
performed for 45 minutes on 100 V. In the end gel was checked and photographed under UV 
light.  
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4. RESULTS AND DISCUSSION 
 The aim of this thesis was to see how certain deletions in the chromosome of the selected 
strains influence cell growth and plasmid stability in different cultivation volumes, from shake 
flasks to bioreactors. Segregational stability of plasmids is a major concern for recombinant 
bacterial production strains and one of the best strategies to counteract plasmid loss is the use 
of auxotrophic mutants which are complemented with the lacking gene along with the product-
relevant ones on the plasmid. In this thesis, two strains from Keio collection were used: Keio 
parent strain and Keio tpiA knock-out. Both were transformed with previously plasmid 
pBR322-P100sfGFP-tpiAO, later in text called pGFP-tpiA to make it shorter and easier to 
follow. pGFP-tpiA contains genes for tpiA, sfGFP, under strong constitutive promoter P100, 
and for Ampicillin resistance. Keio parent strain, transformed with pGFP-tpiA, was cultivated 
in HSG medium with Ampicillin and without it, while Keio tpiA knock-out strain, transformed 
with pGFP-tpiA, was cultivated in pure HSG medium. Both strains were cultivated in shake 
flasks and as a batch culture in bioreactor. In addition Keio tpiA knock-out, transformed with 
pGFP-tpiA, was cultivated in fed-batch culture to observe what happens in high cell density 
cultures over longer period of cultivation. During cultivations samples were taken every hour 
or every two hours, depending on growth rate, and analyzed. Every cultivation was repeated 
twice and the results were statistically processed. In the next chapters results are analyzed and 
shown graphically as a comparison of Keio parent strain, transformed with pGFP-tpiA, 
cultivated in pure HSG medium, Keio parent strain, transformed with pGFP-tpiA, cultivated in 
HSG medium with Ampicillin and Keio tpiA knock-out, transformed with pGFP-tpiA, 
cultivated in HSG medium. Finally new Keio tpiA knock-out strain was created and the results 
are shown in last chapter.  
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4.1. Fermentation in shake flasks  
4.1.1. Cell growth  
Growth of cells was monitored by measuring OD600 of samples. Figure 9. shows growth 
curve of the Keio parent and Keio tpiA knock-out strains, transformed with pGFP-tpiA, through 
fermentation in shake flasks. 
 
Figure 9. Growth curve of Keio parent and Keio knock-out strain, transformed with pGFP-
tpiA, cultivated in shake flasks 
 As it can be seen from the graph, Keio parent strain, transformed with pGFP-tpiA, has 
similar growth in medium with and without antibiotic, with a slightly advantage while growing 
in medium without antibiotic. Still, all of the phases are in harmony and take the same time. If 
we compare the growth of the knock-out strain, transformed with pGFP-tpiA, to the 
transformed parent strain, its lag phase is one hour longer, and it is still in the exponential phase 
at 8. hour of growth. This is logical as a knock-out strain is ‘damaged’, and needs more time 
for growing. Cell density reached after 8 hours of cultivation is similar: 7 g/L for Keio knock-
out strain, transformed with pGFP-tpiA, and Keio parent strain, transformed with pGFP-tpiA,  
in medium with Ampicillin, a little bit higher for Keio parent strain, transformed with pGFP-
tpiA,  in medium without antibiotic.   
Comparison of specific growth rate between the strains during cultivations in shake 
flasks are shown on Figure 10.  
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Figure 10. Specific growth rate of cells during cultivation in shake flasks 
As it is expected cells grow faster in medium without antibiotic and culture reaches 
higher cell density, but the problem is that in that medium it is less likely that only desired strain 
that is growing and it is more likely that there are some contaminations or that plasmid is no 
longer present in the culture.  
Keio tpiA knock-out transformed with pGFP-tpiA, shows lower growth rate in 
comparison to the transformed parent strain. This cultivation should be repeated for longer time 
to be sure when the strain reaches stationary phase. 
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4.1.2. Fluorescence 
In order to check what is happening with the plasmid in the culture plasmid stability 
was measured. As plasmid pGFP-tpiA contains gene for sfGFP plasmid stability was 
measured through fluorescence. Figure 11. shows how fluorescence changes during 
cultivation in shake flasks.  
 
Figure 11. Changes in fluorescence during cultivation in shake flasks 
In the beginning fluorescence is low in all variants of fermentation but as soon as the 
cells get into exponential growth (in the third hour), difference can be seen and it is getting 
bigger as the cultivation is going further. Plasmid pGFP-tpiA contains bla gene for ß-lactamase 
which gives it resistance to Ampicillin and as it is expected that plasmid stability is higher in 
cultivations with Ampicillin for transformed Keio parent strain. In medium without antibiotic 
it is not necessary for cells to carry the plasmid and as soon as cells with very low plasmid copy 
numbers show up, preferentially during high grow rates, when cells might have not enough time 
to synthesize plasmids in high copy numbers, they will have advantage. Caused by the 
additional metabolic burden, plasmids may be lost completely, since plasmid-free cells would 
gain a growth advantage in comparison to plasmid-bearing cells (Velur Selvamani et al., 2014).  
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Carbon source in HSG medium is glycerin, and bacteria needs enzyme tri phosphate 
isomerase (tpiA) to grow on it. Knock-out strain, without this enzyme, can grow on this 
medium only when it has plasmid carrying the correct gene for tpiA. As it is expected, this 
selection pressure keeps the plasmid stability high during cultivations. (Velur Selvamani et 
al., 2014).  
The difference in fluorescence reached after 8 hours of cultivation in shake flasks can 
be seen on Figure 12. Fluorescence reached with transformed Keio tpiA knock-out is three 
times higher compared to fluorescence reached with transformed parent strain cultivated in pure 
medium, while fluorescence reached in medium with Ampicillin is 4 times higher. 
 
Figure 12. Fluorescence after 8 hours cultivation in shake flasks  
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4.2. Batch cultivation   
4.2.1. Cell growth 
Figure 13. shows growth curve for cells cultivated in batch fermentation in bioreactor 
NLF3.  
  
Figure 13. Growth curve of Keio parent and Keio knock-out strain, both transformed with 
pGFP-tpiA, during batch cultivation in bioreactor NLF3 
 In this case of transformed Keio parent strain, cells grow faster in the exponential 
phase faster in medium with Ampicillin, otherwise stated, their specific growth rate is higher 
during exponential phase, as it can be seen in Figure 14. Transformed Keio tpiA knock out 
strain in the beginning grows slower than the transformed parent strain cultivated in medium 
with antibiotic but goes through the phases of growth simultaneously as the transformed 
parent strain. Transformed parent strain goes to stationary phase in 6th hour, while 
transformed knock-out strain continues to grow exponentially for four more hours. Cell 
density reached with the transformed parent strain is around 8 g/L while one reached with the 
transformed knock-out strain is 25 g/L.  
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Figure 14. Specifical growth rate of cells during batch cultivation in bioreactor NLF3 
4.2.2. Fluorescence 
Fluorescence measurements during batch cultivation with transformed parent strain are 
shown in Figure 15. In this case there is no big difference in fluorescence between culture grown 
in plain medium and culture grown in medium with Ampicillin. Possible reason for it is that 
preculture was grown in medium with antibiotic in which cells already produced ß-lactamase, 
which then, when added to the bioreactor, degraded the antibiotic present and then there was 
no need for the cells to keep the plasmid. Ampicillin can be degraded by ß-lactamases in less 
than 30 minutes in high cell density cultures (Jung et al., 1988). Also appearance of plasmid-
free segregants is not totally prevented, since the concentration of the antibiotic used for the 
maintaining of plasmid stability often decreases during long term cultivation as a result of 
dilution and/or enzymatic degradation by the growing cells (Hägg et al., 2004). On the other 
side, fluorescence reached with transformed knock-out strain (Figure 16) is more than 200 times 
higher than one reached with the transformed parent strain, as it can be better seen on Figure 
17. So it can be concluded that knock-out strain provides good plasmid stability as an alternative 
to antibiotic makers. 
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Figure 15. Change of fluorescence during batch cultivation in bioreactor NLF3 
 
Figure 16. Change of fluorescence during batch cultivation of Keio tpiA knock-out strain 
during batch cultivation in HSG medium in bioreactor NLF3  
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Figure 17. Fluorescence reached after 8 hours of batch cultivation showed with a logarithmic 
scale  
Finally, if we compare fluorescence reached in shake flasks and in bioreactor cultivation 
with transformed parent strain, fluorescence in shake flasks is 20 times higher in medium 
without antibiotic and even 100 times higher in medium with antibiotic. On the other hand, 
fluorescence reached with the transformed knock-out strain is 5 times higher in batch 
cultivation compared to shake flasks.  
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4.3. Fed-batch cultivation  
 After good results obtained with cultivation of Keio knock-out strain, transformed with 
pGFP-tpiA in batch fermentation, it was repeated with fed-batch to see how growth and plasmid 
stability changes in high density cultures over longer period of time. Figure 18 shows its growth 
curve.  
 
Figure 18. Growth curve of Keio tpiA knock-out strain, transformed with pGFP-tpiA, during 
fed-batch cultivation in HSG medium in bioreactor NLF3  
 Cell density reached during fed-batch cultivation is around 40 g/L. If we compare 
behavior during growth it is similar to batch only that cell grow over longer period because of 
the addition of fresh media. Specific growth rate during exponential phase is 0,8 ± 0,13 h-1 
which is considerably higher than in batch cultivation (0,33 ± 0,14 h-1). 
 Change of fluorescence during cultivation can be seen on Figure 19. Fluorescence 
reached during fed-batch cultivation is similar to those reached during batch cultivation. From 
the graph it can be concluded that plasmid stability is high during cultivation with a slight 
decline in the end of cultivation. Possible problem is that this knock-out strain still contains 
some parts of the tpiA gene, its promoter and terminator. This brings up the possibility of 
recombination between plasmid and cells genome, which could create revertants that would 
grow on HSG medium without plasmid, and probably outgrow plasmid-carrying cells. But to 
make further conclusion this cultivation should be repeated for longer period of time and as a 
continuous culture.  
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Figure 19. Change of fluorescence during fed-batch cultivation of Keio tpiA knock-out strain 
transformed with pGFP-tpiA, during fed-batch cultivation in HSG medium inbioreactor NLF3 
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4.4. Plating   
 During cultivations with both Keio parent and knock-out strain, transformed with pGFP-
tpiA, sterile samples were collected and plated on LB-Amp agar plates to see how their 
appearance and fluorescence changes during time. Plates photographed under UV light are 
shown on Figure 20.  
a)  b)  c)  
d)   e)  f)   
Figure 20. LB-Amp agar plates under UV light after cultivation of Keio parent strain with 
pBR322-P100sfGFP-tpiAO for 1 (a), 24 (b) and 48 (c) hours and cultivation of Keio tpiA 
knock-out strain with pBR322-P100sfGFP-tpiAO after 1 (d), 24 (e) and 48 (f) hours 
 As we see from the pictures transformed Keio parent strain loses fluorescence after 48 
hours but it is still resistant to Ampicillin. The question here is if it became resistant to the 
antibiotic by homologous recombination and lost the plasmid with the gene for sfGFP or the 
sample was contaminated with the Ampicillin resistant strain. Keio tpi-A knock-out keeps 
fluorescence even after 48 hours of cultivation.  
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4.5. Creating a new Keio knock-out strain 
 The Keio collection is comprised of 3985 strains with deletions in duplicate of E. coli 
K‐12 strain BW25113. The problem with the deletions is that all Keio deletion mutants 
contain 21 bp of the 3’ end of the deleted gene, terminator and promoter region and ATG 
codone. This could easily lead to a re-integration of the deleted gene, when present 
completely on a plasmid like it is with the tpiA on pGFP-tpiA. 
To lower the possibility of a homologous recombination between the tpiA gene on the 
plasmid and parts of the tpiA gene, its promotor and terminator, present in the Keio tpiA 
knock-out strain, new knock-out strain was created from Keio parent strain. In this case, new 
knock-out strain doesn’t contain any of the parts of the tpiA gene (Figure 21).  
 
Figure 21. Comparison of tpi-A deletion between Keio tpiA knock-out and new tpiA knock-
out 
Deletion of chromosomal tpiA locus was done using the one-step chromosomal gene 
inactivation technique described by Datsenko and Wanner, 2000. The disrupted gene for tpiA 
was replaced with gene for Kanamycin resistance, with the length of 805 base pairs. Deletion 
has been proven through gel electrophoresis after PCR amplification of fragment between 
bases upstream and downstream of previous tpiA gene. Gel photographed under UV light is 
shown on Figure 22. 
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Figure 22. Gel electrophoresis of KanR fragment in new Keio tpiA knock-out photographed 
under UV-light 
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5. CONCLUSION AND OUTLOOK 
 Within scope of this thesis, growth of two strains, Escherichia coli BW25113 and 
Escherichia coli JW3890-2, both transformed with pBR322-P100sfGFP-tpiAO, was observed 
as well as the plasmid stability. Transformed Escherichia coli BW25113, also known as Keio 
parent strain, was cultivated in HSG medium with and without antibiotic, in shake flasks and 
as batch fermentation in bioreactor. Transformed Escherichia coli JW3890-2, Keio tpiA knock-
out strain, was cultivated in HSG medium, in shake flasks, as batch and as a fed-batch 
fermentation in bioreactor.  
1. In shake flasks, growth of the Keio parent strain, transformed with pGFP-tpiA is 
similar in both variants of fermentation while in medium with antibiotic it is a bit 
slower. Keio tpiA knock-out, transformed with pGFP-tpiA, needs more time to get 
to the exponential phase and grows with a lower growth rate but after 8 hours reaches 
similar cell density as the parent strain.  
Its fermentation should be repeated for longer time to observe when it would reach 
stationary phase and how high would the cell density be in the end.  
2. On the other side plasmid stability during shake flasks cultivation, observed as 
fluorescence, is highest with transformed Keio parent strain cultivated in HSG 
medium with antibiotic. With transformed Keio tpiA knock-out fluorescence 
reached is 65 % of fluorescence reached with Keio parent strain cultivated with 
antibiotic, but it has advantage as antibiotic is not needed for it. Fluorescence 
reached with transformed parent strain in pure medium is only 25 % of fluorescence 
reached in medium with antibiotic respectively 38 % of fluorescence reached with 
transformed mutated strain. 
3. During batch cultivations, transformed Keio tpiA knock-out strain has the lowest 
growth rate but it grows for a much longer time and reaches high cell densities (25 
g/L), three times more than the transformed parent strain. Growth of transformed 
parent strain is similar in both variants of the fermentation, with and without 
antibiotic.  
4. Plasmid stability of the transformed parent strain during batch cultivations is really 
low, and fluorescence reached is more than 100 times lower then fluorescence 
reached with the transformed knock-out strain. Plasmid stability of the knock-out 
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strain, transformed with pGFP-tpiA, is really high and gives good alternative to the 
use of antibiotics in the medium.  
5. In fed-batch cultivation, transformed knock-out strain grows with a higher growth 
rate and reaches higher cell densities but fluorescence reached is similar to those 
reached with batch cultivation.  
For further research growth and plasmid stability in continuous culture should be 
observed.  
 Finally, new strain was created, from Keio parent strain, with deletion of the whole tpiA 
gene. For further research it should be transformed with pBR322-P100sfGFP-tpiAO, and 
cultivated in various volumes, from shake flasks to bioreactor, as a batch, fed-batch and 
continuous culture to observe its growth and plasmid stability and compare it with results 
obtained from cultivation in this thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
6. BIBLIOGRAPHY 
Anonymus (2009) The bacterial growth curve. 
http://principlemicrobiology.blogspot.com/2008/04/bacterial-growth-curve.html. 
Pristupljeno 9.7.2018. 
Baba, T., Takeshi, A., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., 
Tomita, M., Wanner, B. L., Mori, H. (2006) Construction of Escherichia coli K-12 in-
frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2, 1-11 
Blount, Z. D. (2015) The unexhausted potential of E. coli. eLife, 4, e05826. doi: 
10.7554/eLife.05826 
Brinas, L., Zarazaga, M., Saenz, Y., Ruiz-Larrea, F., Torres, C. (2002) β-Lactamases in 
Ampicillin-Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals. 
Antimicrob Agents Ch 46, 3156-3163. 
Cutayar, J. M., Pollon, D. (1989) High cell density culture of E. coli in a fed-batch system 
with dissolved oxygen substrate feed inficator. Biotechnol Let 11, 155-160. 
Dammeyer, T., Tinnefeld, P. (2012) Engineerd fluorescent proteins illuminate the 
bacterial periplasm.  Comput Structural Biotechnol J 3, 4 
Da Silva, G. P., Mack, M., Contiero, J. (2009) Glycerol: A promising and abundant 
carbon source for industrial microbiology. Biotechnol Adv 27, 30-39. 
Datsenko, K. A., Wanner, B. L. (2000) One-step inactivation of chromosomal genes in 
Escherichia coli K-12 using PCR products. P Natl Acad Sci USA 97, 6640-6645. 
Davies, J., Davies, D. (2010) Origins and Evolution of Antibiotic Resistance. Microbiol 
Mol Biol R 74, 417-433. 
Džidić, S., Šušković, J., Kos, B. (2008) Antibiotic Resistance Mechanisms in Bacteria: 
Biochemical and Genetic Aspects. Food Technol Biotech. 46, 11-21. 
Ferrer-Miralles, N., Domingo-Espin, J., Corchero, J. L., Vasquez, E., Villaverde, A. 
(2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 24, 8-17.  
Friehs, K. (2004) Plasmid copy number and plasmid stability. Adv Biochem Eng Biot 86, 
47-82. 
46 
 
Gleband, H., Miller-Petrie, M., Pant, S., Gandra, S., Levinson, J., Barter, D., White, A., 
Laxminarayan, R. (2015) The state of the worlds antibiotics 2015. Wound Healing 
Southern Afr. 8, 30-34. 
Hacker, J., Blum-Oehler, G. (2007) In appreciation of Theodor Escherich. Nat Rev 
Microbiol 5, 902 
Hägg, P., Wa de Pohl, J., Abdulkarim, A., Isaksson, L. A. (2004) A host/plasmid system 
that is not dependent on antibiotics and antibiotic resistance genes for stable plasmid 
maintenance in Escherichia coli. J Biotechnol 111, 17-30. 
Jung, G., Denefle, P., Becquart, J., Mayaux, J. F. (1988) High-cell density fermentation 
studies of recombinant Escherichia coli strains expressing human Interleukin-1-Beta. Ann. 
Inst. Pasteur/Microbiol. 139,129-146. 
Kleist, S., 2002. Optimierung eines fermentativen Verfahrens zur Herstellung einer 
bakteriellen Phytase, Bielefeld (Germany): Bielefeld University 
Lodish, H. F., Berk, A., Kaiser, C. A., Krieger, M., Scott, M. P., Bretscher, A., Ploegh, H., 
Matsudaira, P.  (2008) Molecular Cell Biology, 6. ed, W. H. Freeman and Company, New 
York 
Marić, V., Šantek, B. (2009) Biokemijsko inženjerstvo, Golden marketing-Tehnička 
knjiga, Zagreb 
Modak, J. M., Lim, H. C., Tayeb, Y. J. (1986) General Characteristics of Optimal Feed 
Rate Profiled for Various Fed-Batch Fermentation Processes. Biotechnol Bioeng 28, 1396-
1407 
Moulton (2014) Fed-batch fermentation. Elsevier, Woodland 
Neidhart, F. C. (1987) Escherichia coli and Salmonella typhimurium. ASM Press, 
Washington 
Neu, H. C. (1992) The Crisis in Antibiotic Resistance. Science 257, 1064-1073.  
Parija, S. C. (2009) Textbook of Microbiology and Immunology, Elsevier, Haryana 
Pedelacq, J. D., Cabantous, S., Tran, T:, Terwilliger, T. C., Waldo, G. S. (2006) 
Engineering and characterization of a superfolder green fluorescent protein. Nat 
Biotechnol 24, 79-88. 
47 
 
Penesyan, A., Gillings, M., Paulsen, I. T. (2015) Antibiotic Discovery: Combatting 
Bacterial Resistance in Cells and in Biofilm Communities. Molecules. 20(4), 5286-5298. 
Petsch, D:, Anspach, F. B. (2000) Endotoxin removal from protein solutions. J Biotechnol 
76, 97-119. 
Pichersky, E., Gottlieb, L. D., Hess, J. F. (1984) Nucleotide sequence of the triose 
phosphate isomerase gene of Escherichia coli. Mol Gen Genet 195, 314-320. 
Stanbury, P. F., Whitaker, A., Hall, S. J. (1995) Principles of Fermentation Technology. 
2nd edition, Elsevier Science Ltd., Oxford 
Stepanenko, O. V., Stepanenko, O. V., Shcherbakova, D. M., Kuznetsova, I. M., 
Tuoroverov, K. K., Verkhusha, V. V. (2011) Modern fluorescent proteins: from 
chromophore formation to novel intracellular applications. Biotechniques 51, 313-318. 
Šušković, J., Kos, B. (2017) Tehnologija antibiotika, interna skripta i predavanja, Merlin 
Terpe, K. (2006) Overview of bacterial expression systems for heterologous protein 
production: from molecular and biochemical fundamentals to commercial systems. Appl 
Microbiol Biot 72, 211-222 
Theisen, M., Liao, C. J. (2017) Industrial Biotechnology: Escherichia coli as a Host. In: 
Industrial Biotechnology Microorganisms (Wittman, C., Liao, J. C., ured.), Wiley-VCH 
verlag GmbH & Co., Weinham, str. 151-182. 
Tookmanian, E. M., Fenlon, E. E., Brewer, S. H. (2015) Synthesis and protein 
incorporation of azido-modified unnatural amino acids. RSC Adv 5, 1274-1281.  
Tsien, R. Y. (1998) The green fluorescent protein.  Annu Rev Biochem 67, 509-544. 
Velur Selvamani, R.S., Telaar, M., Friehs, K., Flaschel, E. (2014) Antibiotic-free 
segregational plasmid stabilization in Escherichia coli owing to the knockout of 
triosephosphate isomerase (tpiA) Microb Cell Fact. 13, 58 
Ventola, C. L. (2015) The Antibiotic Resistance Crisis. P T. 40(4). 277-2
 
 
7. APPENDIX 
7.1. Bioreactor specification 
Bioreactor model Bioengineering NLF 1 
Process control BioSCADA Bioengineering 
Total volume 7 L 
Reactor diameter (D) 155 mm 
Reactor hight (H) 360 mm 
Impeller diameter (d) 60 mm 
Impeller blade width (a) 21 mm 
Impeller blade height (b) 16 mm 
Blade diameter (c) 30 mm 
Number of blades 6 
Number of stirrer levels 3 
Blade bottom and bioreactor bottom distance 70 mm 
Distance between two stirrers (k) 122 mm 
Distance between the second stirrer and bioreactor bottom 65 mm 
Stirrer blade and air opening 60 mm 
Stirring shafts diameter 12 mm 
Number of baffles 4 
Baffle height (g) 326 mm 
Baffle width (e) 15 mm 
Baffle and bioreactor wall distance (f) 3 mm 
Baffle and bioreactor bottom distance (h) 0 mm 
 
 
 
 
 
 
 
 
 
 
 
 
7.2. NLF 3 bioreactor system scheme 
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